Drug manufacturers and researchers have a moral obligation to design clinical trials that adequately represent the target population for the investigational agent—and these medical products need to be safe and effective for everyone, leading clinical trial experts in oncology say.

“Because we strongly believe that the best oncology treatment is often treatment within a clinical trial, we also owe it to all patients to ensure that all have that benefit available to them,” said Charles Blanke, group chair of SWOG Cancer Research Network.